Mesoblast (ASX:MSB) and Novartis to commercialise remestemcel-L for ARDS – The Market Herald

• Stem cell researcher Mesoblast (MSB) has entered a licence and collaboration agreement with Novartis to commercialise its remestemcel-L therapy drug
• Novartis is a Swiss-based pharmaceutical company with nearly two decades of experience in delivering products to help people with respiratory issues
• The companies will initially target remestemcel-L on treating COVID-19 related and non-COVID-19 related acute respiratory distress syndrome (ARDS)
• The drug is being used in a 300-patient COVID-19 ARDS, study…

Click here to view the original article.